Publications by authors named "Lothar Bergmann"

Claim this Profile
[
[Non-clear cell renal cell carcinoma].
Marit Ahrens, Lothar Bergmann

Urologie· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature Review.
Annemarie Uhlig, Lothar Bergmann, Martin Bögemann, Thomas Fischer, Peter J Goebell

Urol Int· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).
Viktor Grünwald, Philipp Ivanyi, Stefanie Zschäbitz, Manfred Wirth, Peter Staib, Lothar Bergmann

Eur Urol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Interdisciplinary recommendations for the treatment of advanced renal cell carcinoma].
Kurt Miller, Lothar Bergmann, Christian Doehn, Viktor Grünwald, Jürgen E Gschwend

Aktuelle Urol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
Viktor Grünwald, Thomas Hilser, Johannes Meiler, Peter J Goebell, Philipp Ivanyi, Lothar Bergmann

Oncol Res Treat· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview.
Lothar Bergmann, Sarah Weber, Arndt Hartmann, Marit Ahrens

Expert Rev Anticancer Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry.
Arne Strauss, Marianne Schmid, Michael Rink, Michael Moran, Stephan Bernhardt, Lothar Bergmann

Future Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry.
Martin Boegemann, Katrin Schlack, Michael Rink, Stephan Bernhardt, Michael Moran, Lothar Bergmann

Future Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma].
Kurt Miller, Lothar Bergmann, Christian Doehn, Viktor Grünwald, Jürgen E Gschwend

Aktuelle Urol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma.
Peter J Goebell, Philipp Ivanyi, Jens Bedke, Lothar Bergmann, Dominik Berthold

Future Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society.
Lothar Bergmann, Viktor Grünwald, Luise Maute, Marc-Oliver Grimm, Steffen Weikert

Oncol Res Treat· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[What is new in the diagnosis and therapy of renal cell carcinoma?].
Marit Ahrens, Arndt Hartmann, Lothar Bergmann

Dtsch Med Wochenschr· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Frede Donskov, Robert J Motzer, Eric Voog, Elizabeth Hovey, Carsten Grüllich, Lothar Bergmann

Eur J Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Kurt Miller, Lothar Bergmann, Christian Doehn, Jürgen E Gschwend, Markus A Kuczyk

Aktuelle Urol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study.
Peter J Goebell, Edwin Hermann, Ulrich Kube, Christian Doehn, Norbert Marschner, Lothar Bergmann

Oncol Res Treat· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
Marit Ahrens, Sebastian Scheich, Arndt Hartmann, Lothar Bergmann,

Oncol Res Treat· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].
Kurt Miller, Lothar Bergmann, Christian Doehn, Jürgen Gschwend, Ulrich Keilholz

Aktuelle Urol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Systemic therapy of metastatic renal cell carcinoma].
Luise Maute, Lothar Bergmann

Dtsch Med Wochenschr· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[What opportunities does Immuno-oncology indicate for overarching long-term survival?].
Lothar Bergmann, Wolfram Brugger, Wolfgang Herr, Andreas Mackensen, Gabriele Multhoff

Oncol Res Treat· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Iordanis Gravanis, Kyriaki Tzogani, Paula van Hennik, Pieter de Graeff, Petra Schmitt, Lothar Bergmann

Oncologist· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.
Laurence Albiges, Ulrich Kube, Jean-Christophe Eymard, Manuela Schmidinger, Aristotelis Bamias, Lothar Bergmann

Eur J Cancer· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.
Lothar Bergmann, Ulrich Kube, Christian Doehn, Thomas Steiner, Peter J Goebell

BMC Cancer· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practice.
Lothar Bergmann, Jochaim Beck, Kathrin Bothe, Olaf A Brinkmann, Stephan Buse

Oncol Res Treat· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
Luise Maute, Viktor Grünwald, Steffen Weikert, Ulrich Kube, Thomas Gauler, Lothar Bergmann

J Cancer Res Clin Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temsirolimus for advanced renal cell carcinoma.
Lothar Bergmann, Luise Maute, Michael Guschmann

Expert Rev Anticancer Ther· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis